Close

Streetinsider.com's Hot Lunchtime Reads 10/31: (MCD) (HOG) (CHPR) (REGN) Oct 31, 2016 12:21PM
Roth Capital Confident in Full Sarilumab Approval; Affirms Regeneron (REGN) at 'Buy' Oct 31, 2016 11:18AM
Streetinsider.com's Hot Lunchtime Reads 10/3: (REGN) (AAPL) (NGVT) (CTSH) Oct 3, 2016 12:05PM
Roth Capital 'Impressed' by Latest Dupixent Data; Affirms Regeneron (REGN) at 'Buy' Oct 3, 2016 11:20AM
Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMD Sep 30, 2016 10:16AM


Sep 26, 2016 12:09PM Streetinsider.com's Hot Lunchtime Reads 9/26: (REGN) (ONTX) (LITE) (SFL)
Sep 26, 2016 11:16AM Roth Capital Reaffirms Regeneron (REGN) at 'Buy'; Dupilumab BLA in AD Key Next Step in Development
Sep 20, 2016 12:22PM Roth Capital Reiterates Regeneron (REGN) at 'Buy' Following New Teva Pharma Ffasinumab Partnership
Aug 5, 2016 10:45AM Notable Analyst Rating Changes 8/5: (SYMC) (COH) (OAS) Upgraded; (ICPT) (PKI) (REGN) Downgraded
Aug 4, 2016 02:55PM Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues
Apr 1, 2016 10:55AM Roth Expects Full Approval of Regeneron (REGN) Dupilumab, Trims PT to $520
Feb 10, 2016 11:53AM Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on Pullback
Jan 19, 2016 08:25AM Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
Jul 28, 2015 02:51PM Roth Capital Positive on Regeneron (REGN) Following 'Impressive' Deal with Sanofi (SNY)'; Affirms at 'Buy'
Jul 27, 2015 08:57AM Regeneron (REGN) Investors Already Pricing-in Praluent Approval; Roth Capital Affirms at 'Neutral'
Jul 9, 2015 10:28AM Notable Analyst Rating Changes 7/9: (TRV) (MBLY) (JBHT) Upgraded; (SHAK) (REGN) (VR) Downgraded
May 21, 2015 09:37AM Roth Lifts PT on Regeneron (REGN) to $495 Following Sarilumab Phase 3 Results in RA
May 18, 2015 03:35PM Roth Affirms Regeneron (REGN) at 'Neutral'; Dupilumab Success in Asthma Largely Priced-in
May 7, 2015 01:21PM Regeneron Pharma (REGN) PT Lifted to $490 at Roth Capital
Feb 20, 2015 10:46AM Notable Analyst Rating Changes 2/20: (MRVL) (DSW) (KN) Upgraded; (FUEL) (HLSS) (REGN) Downgraded
Feb 19, 2015 04:44PM Roth Capital Downgrades Regeneron (REGN) to Neutral; Pipeline Opportunities Largely Priced In
Feb 11, 2015 08:54AM Regeneron (REGN) Misses Q4 GAAP EPS Views on R&D, Pipeline Expansion, but EYLEA Shaping-Up Well - Roth Capital
Jan 26, 2015 09:41AM Regeneron (REGN), Sanofi (SNY) on 'Last Stretch' of Praluent Development - Roth Capital
Dec 1, 2014 02:20PM Regeneron's (REGN) Eylea sBLA Receives Priority Review as DME + Diabetic Retinopathy Treatment; Roth Capital Comments
Nov 20, 2014 12:17PM Streetinsider.com's Hot Lunchtime Reads 11/20: (LB) (AMZN) (REGN) (GS) (FB)
Nov 20, 2014 10:46AM Regeneron's (REGN) Dupilumab Receives FDA Breakthrough Designation; Roth Capital Comments
Nov 19, 2014 11:02AM Roth Comments on Regeneron (REGN) Following ODYSSEY Update at AHA (SNY)
Oct 17, 2014 09:01AM Roth Capital Remains Positive on Regeneron (REGN); Latest Outcome Better Positions Eylea as Superior DME Treatment
Oct 7, 2014 07:49AM Roth Keeps Regeneron (REGN) at 'Buy'; Another Eylea Approval is No Surprise
Sep 30, 2014 10:44AM Latest Data for Regeneron's (REGN) Dupilumab Broadens Benefit Profile - Roth
Sep 3, 2014 11:03AM Roth Lifts Price Target on Regeneron (REGN) to $422 Following ODYSSEY Phase III Updates
Aug 11, 2014 03:34PM Roth Capital Comments on Regeneron (REGN) After EC Approves Eylea for DME Patients
Aug 5, 2014 12:29PM Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
Jul 30, 2014 10:03AM Roth Boosts PT on Regeneron (REGN) to $399 Following ODYSSEY Phase III Data, EYLEA Approval
Jul 18, 2014 09:43AM Roth Capital Affirms Regeneron (REGN) at 'Buy'; Comments on Eylea Phase III VIVID-DME Two-Year Data
Jul 10, 2014 08:29AM Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Positive Dupilumab Phase 2b Update
Jun 12, 2014 11:10AM Roth Comments on Regeneron (REGN), Sanofi Presentation of Sarilumab Phase 3 Data; Affirms at 'Buy'
Jun 11, 2014 11:27AM Roth Comments on Regeneron's (REGN) MAA Submission for EYLEA to EU; Reaffirms 'Buy' Rating
Apr 1, 2014 09:50AM Roth Sees Regeneron/Sanofi Alirocumab Phase 2 Results as Positive; Maintains 'Buy' Rating (REGN)
Mar 31, 2014 01:59PM Roth Raises PT on Regeneron (REGN) to $382; ODYSSEY MONO, Alirocumab Data Bolsters Positive Outlook
Mar 31, 2014 01:49PM Regeneron Pharma (REGN) PT Raised to $382 at Roth Capital
Feb 13, 2014 10:49AM Notable Analyst Rating Changes 02/13: (ANR) (ATHN) (NSPH) Upgraded; (DEPO) (REGN) (AEM) Downgraded
Feb 12, 2014 01:26PM Roth Keeps Regeneron (REGN) at 'Buy' Following Q4 Numbers, Outlook; VISTA, OUTLOOK Still in Focus
Feb 12, 2014 10:38AM Notable Analyst Rating Changes 02/12: (CROX) (S) (ZTS) Upgraded; (AMZN) (DF) (GMCR) Downgraded
Jan 14, 2014 09:24AM Regeneron (REGN) Remains Strong Buy Following Recent Positive News - Roth Capital
Jan 17, 2012 07:57AM Roth Capital Downgrades Regeneron Pharma (REGN) to Neutral
Nov 10, 2011 10:36AM Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
Oct 26, 2011 11:22AM Notable Analyst Rating Changes 10/26: (AMTD) (NFLX) (REGN) Upgraded; (HGSI) (FSLR) (MF) Downgraded
Sep 12, 2011 08:17AM Roth Capital Starts Regeneron Pharma (REGN) at Neutral
Aug 31, 2011 01:15PM Regeneron (REGN) Shares Trade Up on FDA Alert on Avastin
Aug 8, 2011 08:44AM Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
Apr 7, 2011 09:06AM Roth Capital Upgrades Regeneron Pharma (REGN) to Neutral
Jan 7, 2010 07:53AM Roth Capital Initiates Coverage on Biotechnology and Drugs Stocks